Marty Makary
speaker
939 appearances
6 recordings
5 series
first heard Jan 2026
last heard 13 May
Marty Makary’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 6 in all, peaking in Jan 2026 with 4.
Appearances
Great.
Well, look, let's start with a framing.
The framing is the US versus China.
I want to read this report that came from the Congressional National Security Commission on Emerging Biotechnology.
We're here at a biotech conference, so I figured we could start here because everyone's talking about China and the race against China.
The US, according to this commission, has a three-year window to act to keep up with Chinese innovation and the speed in biotech.
In 2022, Chinese companies were just 5% of licensing deals.
2025, 42%.
And recently, one of the biggest licensing deals ever was 3S Bio, $1.25 billion upfront with a $6 billion total with Pfizer.
China had, 10 years ago, only 50% of published scientific papers to the US.
Today, they're 50% more than the US.
So I just want to walk through your view on US biopharma innovation as it relates to China.
Is there a race?
And if so, what are the priorities for the administration in helping American biotech industry remain competitive?
As you think about those work streams in improving the efficiency, turnaround time, how much can you do this on your own versus how much do you need Congress to act to pass legislation to support those changes?
And are there priorities that you're working with Congress on to try and accelerate drug approval timelines that are necessary?
And going back to this point about cutting down on timelines for phase one, two, three, maybe you can just for the audience that may not work in this industry, very briefly explain phase one, two, three, and then where we think there's the biggest kind of, call it excess regulatory burden that's causing these extended timelines on drug approvals, just to kind of frame it up a little bit.
You're making me sick, because this has always been, from my point of view, one of the most troubling bioethical concerns I've had about the industry, because you don't get a lot of statistical power or benefit from doing this, and it's just awful that we do it.
And if we don't, then we're also putting our industry at risk.
So the drug company gets a voucher if they qualify under one of those three criteria and that gives them a fast track?
Showing 681–700 of 939 · page 35 of 47
← Previous
Next →